SCL

Stepan Company (SCL) 2025 Annual Report Summary

Business Context and Reporting Period

This summary covers the Form 10-K for Stepan Company for the fiscal year ended December 31, 2025. Stepan is a global producer of specialty and intermediate chemicals operating through three reportable segments: Surfactants (71% of sales), Polymers (25% of sales), and Specialty Products (4% of sales). The company serves diverse end markets including consumer products, construction, agriculture, and pharmaceuticals. As of December 31, 2025, the company employed 2,328 persons.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 7% driven by higher average selling prices (+$130.7 million) and a 1% increase in volume. Price increases were primarily due to raw material cost pass-throughs and favorable product mix.
• Segment Performance:
  • Surfactants: Sales rose 9% to $1.67 billion, but operating income fell 21% to $67.4 million due to lower unit margins and higher operating expenses.
  • Polymers: Sales remained flat at $584.5 million; operating income increased 7% to $43.3 million.
  • Specialty Products: Sales surged 29% to $81.7 million with operating income up 23% to $25.6 million.
• Corporate Expenses: Decreased 25% year-over-year, largely due to the non-recurrence of a $6.8 million fraud charge from 2024 and $15.9 million in gains from asset sales.
• Asset Sales: The company completed the sale of manufacturing assets in the Philippines (gain of $5.1 million) and Lake Providence, Louisiana (gain of $10.8 million) in Q4 2025.
• Impairments: A $6.2 million goodwill impairment charge was recorded for the Mexico reporting unit.

Guidance, Outlook, and Risks

• Project Catalyst: In February 2026, management announced "Project Catalyst," an operational efficiency plan targeting approximately $100 million in pre-tax savings over two years.
• Restructuring: The Board approved plans to shut down the Fieldsboro, NJ site and decommission assets at Elwood, IL, and Stalybridge, UK, in H1 2026. Total restructuring expenses are expected to range from $70 million to $80 million in 2026.
• Capital Expenditures: Estimated at $100 million to $110 million for 2026.
• Key Risks:
  • Regulatory: Ongoing compliance costs related to 1,4-dioxane regulations and ethylene oxide emissions. A $1.1 million FIFRA penalty was paid in 2025 (partially recovered).
  • Environmental: Significant contingencies exist for remediation at sites including Maywood, NJ, and Wilmington, MA. Estimated potential losses range from $19.3 million to $46.0 million.
  • Cybersecurity: The company remains exposed to cyber threats, following a $6.8 million social engineering fraud loss in 2024.
  • Market: Volatility in raw material and energy costs, and potential demand reduction due to customer reformulations.

Investor Verification Checklist

• Asset Sale Proceeds: Verify the timing of cash inflows from the Philippines and Louisiana asset sales and the sustainability of the tolling agreement in Southeast Asia.
• Restructuring Costs: Monitor the execution of the $70M-$80M restructuring plan in 2026 and its impact on near-term earnings.
• Surfactant Margins: Assess the ability to maintain margins in the Surfactants segment given the 21% drop in operating income despite revenue growth.
• Environmental Liabilities: Review updates on the Maywood, NJ, and Wilmington, MA remediation costs, as actual costs could materially exceed current accruals.
• Debt Covenants: Confirm continued compliance with debt covenants, specifically the 3.50:1.00 interest coverage and net leverage ratios, amidst the planned restructuring spend.